Corvus Pharmaceuticals (CRVS) Cash from Investing Activities (2015 - 2026)

Corvus Pharmaceuticals' Cash from Investing Activities history runs 12 years deep, the most recent figure standing at -$144.8 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 3513.76% year-over-year to -$144.8 million; the TTM figure through Mar 2026 stood at -$156.9 million (down 575.24% YoY), while the FY2025 annual figure was -$7.8 million, up 71.63% from the prior year.
• Cash from Investing Activities was -$144.8 million for Q1 2026 at Corvus Pharmaceuticals, down from $10.9 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $17.5 million in Q3 2023 to a low of -$144.8 million in Q1 2026.
• Historically, Cash from Investing Activities has averaged -$11.1 million across 5 years, with a median of -$2.6 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Cash from Investing Activities surged 60714.29% in 2025, then sank 3513.76% in 2026.
• A 5-year view of Cash from Investing Activities shows it stood at -$3.9 million in 2022, then soared by 40.29% to -$2.3 million in 2023, then sank by 162.42% to -$6.1 million in 2024, then jumped by 278.86% to $10.9 million in 2025, then sank by 1431.31% to -$144.8 million in 2026.
• The last three Cash from Investing Activities figures came in at -$144.8 million (Q1 2026), $10.9 million (Q4 2025), and -$2.6 million (Q3 2025), per Business Quant data.